Navigation Links
Independent Data Safety Monitoring Board Recommends Continuation of Sangart's Pivotal Phase III Trials of Hemospan(R)
Date:12/13/2007

SAN DIEGO, Dec. 13 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, today announced that an independent data safety monitoring board (DSMB) has recommended the continuation of both Phase III clinical trials of Sangart's lead blood substitute product, Hemospan(R), under current protocols.

This recommendation follows the DSMB's review of the blinded data from the first one-third of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe. The DSMB will conduct another review after two- thirds of the patients have been enrolled.

"We are pleased to have the DSMB's approval and look forward to advancing these important Phase III studies," commented Dr. Robert Winslow, Chairman, President and CEO of Sangart.

Hemospan is a hemoglobin-based oxygen transport agent designed to serve as an oxygen therapeutic and as an alternative to blood transfusions. A key property of Hemospan is its high oxygen affinity which results in targeted oxygen delivery to tissues at risk of oxygen deprivation.

About Sangart

Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as oxygen transport agents.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. From this experience, Sangart's lead product, Hemospan, was designed using unique polye
'/>"/>

SOURCE Sangart, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
8. Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
11. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., Dec. 2 TechConnect World, an eve...elopment and product integration in cleantech, nan...th deadline for technology abstracts and business ...nect World, in association with the Nano Science a...nology and Sustainable Industries Organization (CT...
(Date:12/2/2009)...c. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy,...etin Board: EMDY), a leading,producer and distribu...and,soybean products in China, today announced tha... of US Food & Drink Executive, a quarterly mag... in the food and beverage industry. , The...
(Date:12/2/2009)...2 /PRNewswire-Asia/ -- The world is going through,...certainty is part of many,businesses and industrie...relatively immune to the economic downturn, becaus...ng the midst of the difficult times this year, the...rated an R&D center in Shanghai, the largest o...
(Date:12/1/2009)...y Solomon announced that he has joined Carolina Ey...ebsite at www.DrKerrySolomon.com , which was deve... a proven LASIK, lens implant, and cataract surger...r his substantial contributions to improving visio...ASIK Surgeons, which screens LASIK surgeons based ...
Breaking Biology Technology:Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...,ICAD), an industry-leading provider of Computer-A...tion of cancer, today announced that John,DeLucia ...ssurance and,Regulatory Affairs, reporting to iCAD...ore than 25 years of medical device, in-vitro diag... key management position. Mr.,DeLucia has signific...
...Inc. (OTC Bulletin Board: AVGO), a late stage biot...stem therapeutics for neurodegenerative,diseases, ... Administration,(FDA) and will proceed with a Phas...the treatment of Huntington,s disease, pending fin...., A double-blind, placebo-controlled Phase III c...
...dcast you,will learn about how plant biotechnology...ate stress., Climatic conditions such as heat or ...arvest turns out well or badly. Because whenever t...themselves in a stressful,situation, literally. On...farmer,s work goes far beyond the mere production ...
Other Biology Technology:iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs 2iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs 3Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial 2Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial 3Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial 4BASF Podcast - Better Harvest in Spite of Climate Stress 2BASF Podcast - Better Harvest in Spite of Climate Stress 3
(Date:12/4/2009)...ording to an analysis of statewide data taken from...,000 a year were more than three times likely to r...oviders because of their insurance status during p... of insurance-based discrimination was also three ...rage, and four times more likely among women who d...
(Date:12/4/2009)...Royal Botanic Gardens, Kew and the Natural History...ts is far more widespread than previously thought,... at least part way to being "meat eaters". A revi...in and modern insights into vegetable carnivory, i...cal Journal of the Linnean Society . , Carnivoro...
(Date:12/4/2009)...ilable in German . , A new study of the Max P...o understand the positive effect of dietary restri...fferent organisms (fruit flies and mice) have show...t with a potential negative side effect of diminis...less frequently with a reduced litter size on a lo...
Breaking Biology News(10 mins):Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2Winner Medical Schedules 2008 2009 Third Quarter Earnings Release on Tuesday August 11 2009 53833 1Winner Medical Schedules 2008 2009 Third Quarter Earnings Release on Tuesday August 11 2009 53833 2Genomic Health to Present at Canaccord Adams 29th Annual Global Growth Conference 53829 1Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 1Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 2Gold Standard Elsevier Launches MedCounselor Consumer Drug Information Modules 53825 3
...ty of Bath have won a £261,000 grant to use the la... drug that could stop influenza and some other dis...ent of the grant comes at a time when fears are ri...ian chickens could kill thousands of people. , Pr...ry, will begin work in April on a project that cou...
... present a “cautionary tale?about what may go wron...o devise a diagnostic test for cancer. , In the F...ncer Institute, researchers from The University of...experimental test intended to identify early ovari... to lead to a reliable clinical test right away. ,...
... combining,nanoparticle and gene silencing technol...us (RSV) -- a virus associated with severe,bronchi...outh Florida,researchers found. The study was repo...re Medicine.,RSV infects lung cells and can be lif...and those with compromised immune systems. No,vacc...
Other Biology News:Computers to be used to find blueprint for new influenza drug 2New species from old data 2New species from old data 3Novel antiviral technology inhibits RSV infection in mice 2
...eening and binding optimization and built on the f...synthesis platform. These microarrays are availabl...roarray Service. Probe Content Our Standard DNA...wn aptamer sequences. Add up to 100 of your own cu...
...vice for custom peptide microarray experiments uti...d on Paraflo microfluidic chips for quantitative a...um samples. This comprehensive service includes as...s using sample(s) provided by you, single or dual ...
...tope analysis service utilizing high density pepti... chips for immunological studies, vaccine developm... service includes assistance with your sequence de...you, single or dual color detection of the binding...
...eening and binding optimization and built on the f...synthesis platform. Thousands of customer specifie...Sciences can provide assistance with custom sequen... of our comprehensive DNA/RNA Aptamer Microarray S...
Biology Products: